Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

Sieghart Sopper, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjorn T. Gjertsen, Guenther Gastl, Matthias Baldauf, Zlatko Trajanoski, Frank Giles, Andreas Hochhaus, Thomas Ernst, Thomas Schenk, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Kimmo Porkka, Dominik Wolf

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)175-+
JournalJournal of Clinical Oncology
Volume35
Issue number2
DOIs
Publication statusPublished - 10 Jan 2017

Cite this